BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual MeetingGlobeNewsWire • 11/11/24
BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024GlobeNewsWire • 09/16/24
BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024GlobeNewsWire • 09/16/24
BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, PlinabulinGlobeNewsWire • 09/03/24
SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology IndicationsGlobeNewsWire • 08/06/24
BeyondSpring R&D Day Highlights New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsGlobeNewsWire • 05/16/24
BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED TherapeuticsGlobeNewsWire • 05/03/24
BeyondSpring Provides Business Update and Reports Year End 2023 Financial ResultsGlobeNewsWire • 04/29/24
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung CancerGlobeNewsWire • 03/25/24
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-KGlobeNewsWire • 01/10/24
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 InhibitorGlobeNewsWire • 11/07/23
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of DirectorsGlobeNewsWire • 10/23/23
BeyondSpring and Leading Cancer Center to Present Poster at SITC's 38th Annual MeetingGlobeNewsWire • 09/27/23
BeyondSpring to Participate in the R.W. Baird's 2023 Global Healthcare ConferenceGlobeNewsWire • 09/07/23
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual MeetingGlobeNewsWire • 05/18/23
BeyondSpring Provides Business Update and Reports Year End 2022 Financial ResultsGlobeNewsWire • 04/18/23
BeyondSpring Receives Notifications from Nasdaq Regarding Compliance With Listing RulesGlobeNewsWire • 01/09/23
BeyondSpring Presents Positive Data with Plinabulin for the Prevention of Docetaxel-Induced Neutropenia in Patients with Non-Small Cell Lung Cancer and Breast Cancer at Three Medical ConferencesGlobeNewsWire • 12/13/22
BeyondSpring Presents New Clinical Evidence of Plinabulin Protection of Granulocyte-Monocyte Progenitor Stem Cells for the Prevention of Chemotherapy-Induced Neutropenia at the ESMO Congress 2022GlobeNewsWire • 09/13/22
BeyondSpring Presents New Data for the Use of Plinabulin and Pegfilgrastim to Decrease Neutropenia Burden in Peri-Transplant Multiple Myeloma Patients at the 19th International Myeloma Society Annual MeetingGlobeNewsWire • 08/29/22
BeyondSpring Presents New Clinical Data in the Chemotherapy-Induced Neutropenia and NSCLC Programs at the 2022 ASCO Annual MeetingGlobeNewsWire • 05/27/22
